Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination Wegovy ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The company CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade probe ...

The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Sen. Bill Cassidy’s report calls on Congress to improve the transparency of the drug discount program in a move praised by ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...